한빛사204건

• • 한지원(가톨릭대학교 서울성모병원)

  • 강민우(가톨릭대학교 의과대학)

  • 성필수(가톨릭대학교 의과대학 서울성모병원)

  Dynamic peripheral T-cell analysis identifies on-treatment prognostic biomarkers of atezolizumab plus bevacizumab in hepatocellular carcinoma

  • Liver Cancer September 02 2024 | https://doi.org/10.1159/000541181

  • 2024.09
  • 의약학

• • 김부겸(고려대학교)

  • 오상철(고려대학교)

  Cannabidiol enhances Atezolizumab efficacy by upregulating PD-L1 expression via the cGAS-STING pathway in triple-negative breast cancer cells

  • Cancer Immunol. Res. September 03 2024 | https://doi.org/10.1158/2326-6066.CIR-23-0902

  • 2024.09

• • 문상준(서울대학교)

  • 정문교(서울대학교, 현 삼성바이오로직스)

  • 김병수(서울대학교)

  Engineered Nanoparticles for Enhanced Antitumoral Synergy Between Macrophages and T Cells in the Tumor Microenvironment

  • Adv. Mater. Sep 10 2024, | https://doi.org/10.1002/adma.202410340

  • 2024.09
  • 바이오·의료융합

• • 이상희(Northwestern University)

  • 고민준(Northwestern University)

  • 김동현(Northwestern University)

  Cryo-Nanocatalyst Enhances Therapeutic Efficacy of Cryo-Immunotherapy through Necroptosis and Local Delivery of Programmed Death-Ligand 1 Inhibitors

  • ACS Nano Aug 22 2024, | https://doi.org/10.1021/acsnano.4c05809

  • 2024.08
  • 바이오·의료융합

• • 박은정(Mie University Graduate School of Medicine)

  Roles of programmed death-1 and muscle innate lymphoid cell-derived interleukin 13 in sepsis-induced intensive care unit-acquired weakness

  • J. Cachexia Sarcopenia Muscle 17 July 2024 | https://doi.org/10.1002/jcsm.13548

  • 2024.07
  • 의약학

• • 김윤재(광주과학기술원)

  • 김기현(광주과학기술원, 지놈앤컴퍼니)

  • 김수정(광주과학기술원)

  • 박한수(광주과학기술원, 지놈앤컴퍼니)

  • 박숙련(울산대학교 의과대학, 서울아산병원)

  Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor

  • Cell Host Microbe July 25, 2024 | https://doi.org/10.1016/j.chom.2024.06.010

  • 2024.07
  • 의약학

• • 최윤정(시프트바이오, 고려대학교)

  • 김성아(고려대학교, 한국과학기술연구원)

  • 남기훈(시프트바이오, 고려대학교)

  • 권민수(울산대학교 의과대학)

  • 김인산(고려대학교, 한국과학기술연구원)

  Novel insights into paclitaxel‘s role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment

  • J. Immunother. Cancer Jul 15 2024, 12 (7) e008864 | https://jitc.bmj.com/content/12/7/e008864

  • 2024.07
  • 의약학

• • 전흥진(충남대학교)

  • 임대진(강원대학교 의생명과학대학 의생명융합학부)

  • 정재호(전남대학교 의과대학)

  • 송미령(한국외국어대학교)

  • 이효진(충남대학교 의과대학, 충남대학교병원)

  Controlling tumor progression and recurrence in mice through combined treatment with a PD-L1 inhibitor and a designer Salmonella strain that delivers

  • Acta Pharm. Sin. B Available online 10 July 2024 | https://doi.org/10.1016/j.apsb.2024.07.011

  • 2024.07
  • 의약학

• • 장현지(서울대학교)

  • 민혜영(서울대학교)

  • 이호영(서울대학교)

  Tobacco-induced hyperglycemia promotes lung cancer progression via cancer cell-macrophage interaction through paracrine IGF2/IR/NPM1-driven PD-L1 expr

  • Nat. Commun. Jun 08 2024, 15 (1) | https://doi.org/10.1038/s41467-024-49199-9

  • 2024.06
  • 생명과학

• • 김예리(한국과학기술연구원 (KIST))

  • 김선화(한국과학기술연구원(KIST), 고려대학교)

  • 양유수(한국과학기술연구원, UST KIST School)

  Design of PD-L1-Targeted Lipid Nanoparticles to Turn on PTEN for Efficient Cancer Therapy

  • Adv. Sci. Mar 23 2024, | https://doi.org/10.1002/advs.202309917

  • 2024.03
  • 바이오·의료융합

• • 김주원(고려대학교 안암병원)

  • 이효진(충남대학교 의과대학, 충남대학교병원)

  • 사경하(고려대학교 의과대학)

  • 박경화(고려대학교 의과대학)

  Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metasta

  • J. Immunother. Cancer Mar 13 2024, 12 (3) e008638 | https://doi.org/10.1136/jitc-2023-008638

  • 2024.03
  • 생명과학

• • 김영승(STCube Pharmaceuticals)

  BTN1A1 is a novel immune checkpoint mutually exclusive to PD-L1

  • J. Immunother. Cancer Mar 14 2024, 12 (3) e008303 | https://doi.org/10.1136/jitc-2023-008303

  • 2024.03

• • 박종근(가톨릭대학교)

    Interview

  • 최호중(가톨릭대학교)

  • 류재용(덕성여자대학교)

  • 성필수(가톨릭대학교 의과대학 서울성모병원)

  Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepa

  • Hepatology Feb 15 2024, | https://doi.org/10.1097/HEP.0000000000000772

  • 2024.02
  • 의약학

• • Ayeskanta Mohanty(전남대학교)

  • 이민규(광주과학기술원)

  • 이재영(광주과학기술원)

  • 박인규(전남대학교)

  “Three-in-one“: A Photoactivable Nanoplatform Evokes Anti-Immune Response by Inhibiting BRD4-cMYC-PDL1 Axis to Intensify Photo-Immunotherapy

  • Adv. Healthc. Mater. Feb 26 2024, | https://doi.org/10.1002/adhm.202304093

  • 2024.02
  • 바이오·의료융합

• • 이은지(한국한의학연구원)

    Interview

  • 최장기(한국한의학연구원)

  • 정환석(한국한의학연구원)

  Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B ta

  • Phytomedicine Jan 17 2024, 125 S0944-7113(24)00035-7 | https://doi.org/10.1016/j.phymed.2024.155370

  • 2024.01
  • 의약학

• • 송노준(The Ohio State University)

  mRNA vaccines against SARS-CoV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer

  • J. Immunother. Cancer Jan 04 2024, 12 (1) e007922 | https://doi.org/10.1136/jitc-2023-007922

  • 2024.01

• • 김태곤(Vanderbilt University Medical Center)

  PD-1H/VISTA mediates immune evasion in acute myeloid leukemia

  • J. Clin. Invest. Dec 07 2023, e164325 | https://doi.org/10.1172/JCI164325

  • 2023.12

• • 오수현(울산과학기술원 (UNIST))

  • 이지혜(울산과학기술원 (UNIST))

  • 이상준(울산과학기술원 (UNIST))

  Integrated NLRP3, AIM2, NLRC4, Pyrin inflammasome activation and assembly drive PANoptosis

  • Cell. Mol. Immunol. 27 November 2023 | https://doi.org/10.1038/s41423-023-01107-9

  • 2023.11
  • 생명과학

• • 김창곤(연세대학교 의과대학)

  • 고준영(KAIST, 이노크라스)

  • 신수진(연세대학교의과대학 강남세브란스병원)

  • 신지희(한국식품연구원)

  • 정희철(연세대학교의과대학 강남세브란스병원)

  • 이정석(KAIST, 이노크라스)

  • 남영도(한국식품연구원)

  • 정민규(연세대학교 의과대학)

  Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response

  • Cell Rep. Med. October 26, 2023 | https://doi.org/10.1016/j.xcrm.2023.101251

  • 2023.10
  • 의약학

• • 박준식(연세대학교 의과대학)

    Interview

  • 이정윤(연세대학교 의과대학)

  Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysi

  • J. Immunother. Cancer Oct 2023, 11 (10) e007444 | https://doi.org/10.1136/jitc-2023-007444

  • 2023.10
  • 의약학